Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
N4 Pharma ( (GB:N4P) ) just unveiled an update.
N4 Pharma has announced the appointment of Dr. Alastair Smith as an independent Non-Executive Director, following the retirement of David Templeton. Dr. Smith’s experience with Avacta, a leading biotech company, is expected to be instrumental in the commercialization of Nuvec® and the advancement of N4 Pharma’s innovative therapies. The appointment highlights the company’s strategy to strengthen its leadership as it works towards significant licensing deals and collaborations within the gene therapy industry. Dr. Smith’s insights are anticipated to enhance N4 Pharma’s market positioning by promoting its unique gene delivery platform, Nuvec®, which is poised to address critical issues in the gene therapy market.
More about N4 Pharma
N4 Pharma is a biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to advance therapies for cancer and other diseases. The company aims to build a differentiated pipeline through platform licensing deals and partnerships, leveraging Nuvec®’s key advantages in RNA gene delivery, such as multi-therapy delivery, ease of manufacturing, and potential for oral administration.
YTD Price Performance: 0.96%
Average Trading Volume: 1,415,729
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £5.7M
Find detailed analytics on N4P stock on TipRanks’ Stock Analysis page.
